

RESEARCH

Open Access



# EZH2 mediated metabolic rewiring promotes tumor growth independently of histone methyltransferase activity in ovarian cancer

Jianfeng Chen<sup>1,2\*</sup>, Jing Han Hong<sup>3</sup>, Yulin Huang<sup>1</sup>, Shini Liu<sup>4</sup>, Jiaxin Yin<sup>1</sup>, Peng Deng<sup>1</sup>, Yichen Sun<sup>5</sup>, Zhaoliang Yu<sup>6</sup>, Xian Zeng<sup>1</sup>, Rong Xiao<sup>1</sup>, Jason Yongsheng Chan<sup>7</sup>, Peiyong Guan<sup>3,8</sup>, Yali Wang<sup>1</sup>, Peili Wang<sup>1</sup>, Lizhen Liu<sup>9</sup>, Shijun Wen<sup>1</sup>, Qiang Yu<sup>3,8</sup>, Choon Kiat Ong<sup>3,8,10</sup>, Bin-Tea Teh<sup>3,7,8</sup>, Ying Xiong<sup>1</sup> and Jing Tan<sup>1,2,5,9\*</sup>

## Abstract

**Background** Enhancer of zeste homolog 2 (EZH2), the key catalytic subunit of polycomb repressive complex 2 (PRC2), is overexpressed and plays an oncogenic role in various cancers through catalysis-dependent or catalysis-independent pathways. However, the related mechanisms contributing to ovarian cancer (OC) are not well understood.

**Methods** The levels of EZH2 and H3K27me3 were evaluated in 105 OC patients by immunohistochemistry (IHC) staining, and these patients were stratified based on these levels. Canonical and noncanonical binding sites of EZH2 were defined by chromatin immunoprecipitation sequencing (ChIP-Seq). The EZH2 solo targets were obtained by integrative analysis of ChIP-Seq and RNA sequencing data. In vitro and in vivo experiments were performed to determine the role of EZH2 in OC growth.

**Results** We showed that a subgroup of OC patients with high EZH2 expression but low H3K27me3 exhibited the worst prognosis, with limited therapeutic options. We demonstrated that induction of EZH2 degradation but not catalytic inhibition profoundly blocked OC cell proliferation and tumorigenicity in vitro and in vivo. Integrative analysis of genome-wide chromatin and transcriptome profiles revealed extensive EZH2 occupancy not only at genomic loci marked by H3K27me3 but also at promoters independent of PRC2, indicating a noncanonical role of EZH2 in OC. Mechanistically, EZH2 transcriptionally upregulated *IDH2* to potentiate metabolic rewiring by enhancing tricarboxylic acid cycle (TCA cycle) activity, which contributed to the growth of OC.

**Conclusions** These data reveal a novel oncogenic role of EZH2 in OC and identify potential therapeutic strategies for OC by targeting the noncatalytic activity of EZH2.

**Keywords** Ovarian cancer, EZH2, IDH2, TCA cycle, Metabolic rewiring

\*Correspondence:

Jianfeng Chen  
chenjf@sysucc.org.cn  
Jing Tan  
tanjing@sysucc.org.cn

Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

## Background

Ovarian cancer (OC) is among the deadliest cancers worldwide [1]. Most of the OC patients are diagnosed at advanced stages with poor prognosis and limited therapeutic options [2]. Cytoreductive surgery followed by platinum-based chemotherapy remains the standard of care for first-line treatment of OC patients. Even though most patients initially respond to treatment, the high frequency of resistance and relapse hinder the success of contemporary anticancer therapies in OC patients, making OC the leading cause of death in women with gynecological malignancies [3]. Multiple newer therapies, such as antiangiogenic agents, PARP inhibitors and immune checkpoint inhibitors, have been utilized clinically, leading to incremental albeit modest survival improvements in patients with OC. Moreover, the side effects and limited cost-effectiveness of these agents, along with drug resistance, are obstacles for their utilization [4]. Therefore, there is an urgent need to explore novel therapeutics for OC treatment.

DNA copy number alterations are prevalent in OC and drive ovarian tumorigenesis [5]. *EZH2* is an oncogenic driver gene with high copy number amplification [6]. Previous studies have shown that *EZH2* is overexpressed in OC, which promotes cell proliferation and invasion, inhibits apoptosis and enhances angiogenesis [7, 8]. These studies in OC mainly focused on the catalytic function of *EZH2* via its SET domain methyltransferase activity, which confers trimethylation of histone H3 at lysine 27 (H3K27me3) to suppress gene expression [9]. It has been reported that *EZH2* overexpression is associated with poor prognosis in OC and that *EZH2* is positively correlated with the level of H3K27me3 in OC [10, 11]. However, other reports show the loss of H3K27me3 in OC patients, which is correlated with poor prognosis [12]. These contradictory findings have raised questions about whether *EZH2* plays its oncogenic role in OC solely through its H3K27me3 methyltransferase activity, highlighting the need to further clarify the oncogenic mechanisms of *EZH2* in OC.

*EZH2* functions as an important chromatin modifier; however, increasing evidence suggests that *EZH2* can also act as a transcriptional activator [13, 14]. For example, *EZH2* directly transactivates *CCND1* expression to confer a growth advantage independent of its histone methyltransferase activity in natural killer/T-cell lymphoma (NKT) [15]. In prostate cancer, *EZH2* promotes progression via its dual roles: its canonical role in epigenetic silencing of tumor suppressor genes as well as its noncanonical role as a transcription factor in activating AR transcription [16, 17]. Overexpression of *EZH2* occurs frequently in various solid tumors and is correlated with poor prognosis, suggesting that there is a compelling rationale for targeting *EZH2* in cancer [18, 19].

Currently, several *EZH2* inhibitors have been developed for the treatment of hematological malignancies, prostate cancer, sarcoma, and other advanced solid tumors. However, most of these agents are still in preclinical or early-phase clinical trials [20]. In addition, current *EZH2* inhibitors mainly suppress its catalytic methylation activity and thus may have therapeutic limitations due to the prevalent roles of noncatalytic functions of *EZH2* in tumorigenesis. Taken together, these observations indicate that the ability to harness the antitumor effect of *EZH2* inhibitors in OC will remain a clinical challenge, until the mechanisms of *EZH2* in OC have been determined.

In this study, we showed that small molecule-induced degradation, rather than catalytic inhibition, of *EZH2* significantly blocked OC growth in vitro and in vivo. We demonstrated that *EZH2* acts to promote OC in a catalysis-independent manner. We further elucidated that *EZH2* exerts this effect by transcriptionally regulating *IDH2* expression, resulting in metabolic rewiring. Finally, we identified a subset of patients with OC showing higher expression of *EZH2* but a lower H3K27me3 level, which conferred the worst prognosis among OC patients. This study revealed a noncanonical role of *EZH2* in OC and demonstrated that targeting the catalysis-independent activity of *EZH2* is a potential therapeutic strategy.

## Methods

Detailed procedures were provided in Supplemental Methods.

### Clinical samples, cell lines, and reagents

Informed consent was obtained from the patients who provided the tissue samples, and all procedures were approved by the medical ethics committee of the Sun Yat-sen University Cancer Center (Guangzhou, China). All commercial cell lines were purchased from ATCC, except for COV504 (obtained from ECACC). Authentication of cell lines was performed by the authors. The cell lines were maintained in RPMI 1640 medium (HyClone) supplemented with 10% fetal bovine serum (HyClone) and 1% penicillin/streptomycin (Gibco). Mycoplasma testing was performed using the MycoSensor PCR assay kit (Stratagene). DZNep (S7120), GSK126 (S7061) and EPZ-6438 (S7128) were purchased from Selleck Chemicals. YM281 was a kind gift from Dr. S. Wen (Sun Yat-sen University Cancer Center, Guangzhou, China).

### In vivo studies

All animal studies were conducted in compliance with animal protocols approved by the Institutional Animal Care and Use Committee of Sun Yat-sen University Cancer Center (Guangzhou, China). Female BALB/c nude mice (5–6 weeks old) were purchased from Beijing Vital

River Laboratory Animal Technology Company. Tumors were measured with Vernier calipers, and the tumor volume was calculated with the following formula: tumor volume = length  $\times$  width<sup>2</sup>/2. When the tumor volume reached approximately 100 mm<sup>3</sup>, the mice were divided into different groups for treatment. Randomization was performed by equally dividing the tumor-bearing mice with a similar tumor burden into groups for drug treatment. For the EZH2-inducible knockdown xenograft assay, mice were implanted subcutaneously in the flank with  $2 \times 10^6$  OVCAR8 cells with inducible sh-scramble (shSCR) or shEZH2 expression. Doxycycline was dissolved in distilled water and administered by oral gavage at 150 mg/kg daily. For the treatment with DZNep and EPZ-6438, mice were implanted subcutaneously in the right flank with  $5 \times 10^6$  OVCAR8 cells. For the PDX models, PDX-POVC15 tumor masses were passaged in NOD/SCID mice after subcutaneous implantation. When the tumor volumes reached approximately 100 mm<sup>3</sup>, the mice were randomly divided into three groups. DZNep was suspended in 1 $\times$  saline and was given twice a week by intraperitoneal injection (1 mg/kg). EPZ-6438 was dissolved in vehicle consisting of 0.5% weight/volume sodium carboxymethylcellulose and 0.1% volume/volume Tween 80 and given by oral gavage (40 mg/kg daily). For the treatment with YM281, mice were administered vehicle control (80% PBS, 10% castor oil, and 10% DMSO) or YM281 (80 mg/kg) through intraperitoneal injection 6 times weekly. Tumor volume and body weight were monitored twice a week until the tumor volume reached 1,000 mm<sup>3</sup>. Mice were sacrificed by CO<sub>2</sub> inhalation, and tumors were harvested for further analysis.

### Statistical analysis

The data are presented as the mean  $\pm$  SD values unless otherwise specified. Significant differences between two groups were identified using two-tailed Student's *t* test for unpaired data, and *P* < 0.05 was considered to indicate a statistically significant difference. All statistical analyses were performed by GraphPad Prism 9 (La Jolla, CA).

## Results


### Overexpression of EZH2 combined with a low H3K27me3 level correlates with the worst prognosis in patients with OC

To investigate the clinical significance of EZH2 and H3K27me3 in OC, we examined the protein level of EZH2 and the level of H3K27me3 in a cohort consisting of 105 OC patients using an IHC approach. The IHC data indicated that the EZH2 and H3K27me3 levels were not significantly correlated in our cohort of OC patients (Fig. 1A). Patients with high levels of EZH2 exhibited a worse prognosis than those with low levels of EZH2, whereas high levels of H3K27me3

predicted a better prognosis in OC patients (Fig. 1B and C). Based on the patterns of EZH2 expression and the H3K27me3 level, we classified OC patients into four subgroups: EZH2<sup>high</sup>/H3K27me3<sup>high</sup> (11%), EZH2<sup>low</sup>/H3K27me3<sup>low</sup> (45%), EZH2<sup>low</sup>/H3K27me3<sup>high</sup> (19%) and EZH2<sup>high</sup>/H3K27me3<sup>low</sup> (25%) (Fig. 1D). In addition, after stratification of patients by H3K27me3 levels, the EZH2<sup>low</sup>/H3K27me3<sup>high</sup> pattern correlated with the better survival outcomes, and patients in the EZH2<sup>high</sup>/H3K27me3<sup>high</sup> subgroup still had a worse prognosis (Fig. 1E). These observations are consistent with a previous study showing that overexpression of EZH2 with distinct level patterns of H3K27me3 levels correlates with different prognoses in patients with OC, suggesting a decoupling of EZH2 and H3K27me3 in OC tumorigenesis [21]. Furthermore, we showed that in both The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) projects [22] and in our own in-house data, EZH2 was overexpressed in OC tissues compared to the normal tissues, whereas the H3K27me3 level was decreased in OC tissues compared to normal fallopian tube tissues (Fig. 1F-H). Together, these results suggest that the oncogenic role of EZH2 may be independently of its catalytic activity in OC.

### EZH2 functions as an oncogenic driver to promote OC growth independently of its catalytic activity

To investigate the function of EZH2 in OC, we applied 4 inhibitors of EZH2 in three OC cell lines that show high expression of EZH2. The first EZH2 inhibitor described, DZNep has been reported to induce EZH2 degradation and inhibit histone methylation [23]. YM281 was recently reported as a small molecule EZH2 degrader [24]. GSK126 and EPZ-6438 are catalytic inhibitors of EZH2 that bind to its SET domain and compete with the cofactor S-adenosylmethionine (SAM) without affecting the protein stability of EZH2 [20]. Intriguingly, in both the clonogenic growth and cell proliferation assays, DZNep and YM281 but not GSK126 or EPZ-6438 suppressed the growth of OC cell lines (Fig. 2A and B, Supplementary Figure S1A). Using immunoblotting assay, we observed that both DZNep and YM281 could reduce the levels of EZH2 and H3K27me3, whereas GSK126 and EPZ-6438 could decrease only the level of H3K27me3 and did not affect the EZH2 protein level (Fig. 2C). These results suggest that the oncogenic function of EZH2 in OC is independent of its catalytic activity. Consistent with these findings, we observed that DZNep and YM281 but not GSK126 attenuated the capacity of tumor sphere formation (Fig. 2D and Supplementary Figure S1B). The differential efficacies of DZNep, YM281 and EPZ-6438 were further demonstrated in a xenograft model. After continuous dosing with DZNep and EPZ-6438, we found that DZNep but not EPZ-6438 significantly suppressed tumor



**Fig. 1** Overexpression of EZH2 with low H3K27me3 correlates with the worst prognosis in patients with OC

(A) Correlation analysis between EZH2 and H3K27me3 levels in the OC cohort (n = 105). *P* value was determined by Pearson's correlation test

(B) Kaplan-Meier survival analysis for the OC cohort (n = 105), which was divided into EZH2<sup>high</sup> and EZH2<sup>low</sup> subgroups based on the cutoff (cutoff = 6) calculated by the X-Tile software. The *P* value was calculated by log-rank test. \**P* < 0.05

(C) Kaplan-Meier survival analysis for the OC cohort (n = 105), which was divided into H3K27me3<sup>high</sup> and H3K27me3<sup>low</sup> subgroups based on the cutoff (cutoff = 6) calculated by the X-Tile software. The *P* value was calculated by log-rank test. \**P* < 0.05

(D) Representative IHC images of EZH2 and H3K27me3. EZH2 and H3K27me3 levels were detected by IHC staining in a cohort of 105 patients with OC. Scale bar: 100 μm


(E) Kaplan-Meier survival analysis for OC samples (n = 105) in four subgroups, which was classified based on EZH2 (cutoff = 6) and H3K27me3 (cutoff = 6) levels. The *P* value was calculated by log-rank test. \**P* < 0.05, \*\**P* < 0.01

(F) EZH2 log<sub>2</sub>(TPM) value in normal ovarian tissues (GTEx, n = 88) and ovarian cancer tissues (TCGA, n = 426). Data are presented as the mean ± SEM. \**P* < 0.05

(G) Staining score of EZH2 and H3K27me3 levels in fallopian tube and OC tissues. IHC score of EZH2 and H3K27me3 was determined as the scores for the proportion of positively stained tumor cells (1, 1–25%; 2, 26–50%; 3, 51–75%; 4, > 75%) and staining intensity (0, no staining; 1, weak; 2, moderate; 3, strong) by each investigator were multiplied and then averaged. \**P* < 0.05, \*\*\**P* < 0.0001

(H) Representative images of EZH2 and H3K27me3 staining in fallopian tube (n = 33) and OC (n = 105) tissues. Scale bar: 100 μm





**Fig. 2** EZH2 functions as an oncogenic driver to promote OC growth independently of its catalytic activity

(A) Colony formation assay in three OC cell lines. Cells were treated with DMSO or four different EZH2 inhibitors with indicated concentrations for 12 days. Growth medium was changed and inhibitors were also replenished every 3 days. Images are representative of three independent experiments

(B) Cell growth curve of 3 OC cell lines treated with DZNep (1  $\mu$ M), YM281 (5  $\mu$ M), GSK126 (5  $\mu$ M) or EPZ-6438 (5  $\mu$ M) for 96 h. Data are presented as the mean  $\pm$  SD.  $^{*}P < 0.05$ ,  $^{**}P < 0.01$ ,  $^{***}P < 0.001$

(C) Immunoblotting analysis of EZH2 and H3K27me3 in 3 OC cell lines treated with four different EZH2 inhibitors with indicated concentrations

(D) Tumorsphere formation assay of OC cells treated with DZNep (1  $\mu$ M), YM281 (5  $\mu$ M), GSK126 (5  $\mu$ M) for 10–12 days. Data are presented as the mean  $\pm$  SD.  $^{**}P < 0.01$ ,  $^{***}P < 0.001$

(E-F) Xenograft tumor growth (E) and tumor weight (F) of OVCAR8 cells in nude mice treated with saline as control, EPZ-6438 at 200 mg/kg intragastrically daily, or DZNep at 1 mg/kg intraperitoneally twice a week.  $n = 7$  per group. Data are presented as mean  $\pm$  SEM.  $^{**}P < 0.01$ ,  $^{***}P < 0.001$  (Two-way ANOVA with Tukey's post hoc test)

(G) IHC analysis of EZH2, H3K27me3, and Ki67 levels in the excised tumors from (F). Data are presented as mean  $\pm$  SEM.  $^{***}P < 0.001$

(H) Immunoblot analysis of EZH2 and H3K27me3 levels in shEZH2-inducible OVCAR8 cell lines with wildtype or mutant EZH2 restoration. Expression of EZH2-WT and the EZH2- $\Delta$ SET was detected by an EZH2 antibody against residues surrounding Arg354 of human EZH2 protein (SET domain locates in 612–727 amino acids). GAPDH and Histone H3 were used as loading controls

(I) Cell growth curve of shEZH2-inducible OVCAR8 cell lines with wildtype or mutant EZH2 restoration in the presence or absence of Dox at 1  $\mu$ g/mL for 96 h. Data are presented as mean  $\pm$  SD.  $^{***}P < 0.001$

(J) Colony formation assay in shEZH2-inducible OVCAR8 cell lines with wildtype or mutant EZH2 restoration in the presence or absence of 10 ng/mL Dox for 12 days. Growth medium was changed and doxycycline was also replenished every 3 days. Images are representative of three independent experiments

(K) Tumorsphere formation assay of indicated cells treated with or without Dox at 10 ng/mL for 10 days. Data are presented as the mean  $\pm$  SD.  $^{**}P < 0.01$ ,  $^{***}P < 0.001$  vs. EV groups

growth in vivo (Fig. 2E-F). In DZNep-treated tumors, the Ki67 level was decreased concomitantly with the EZH2 but not the H3K27me3 level, further supporting the idea that the oncogenic role of EZH2 is independent of its catalytic methylation activity (Fig. 2G and Supplementary Figure S1C). These results revealed that a reduction in the level of EZH2 but not inhibition of its catalytic activity suppresses the progression of OC.

Since DZNep and YM281 suppressed the proliferation of OC cells by reducing the EZH2 level, the effect of EZH2 depletion in OC was investigated via a doxycycline-inducible Tet-On system expressing EZH2 short hairpin RNA (shRNA). The addition of doxycycline effectively induced the expression of EZH2 shRNA, which drastically decreased the level of EZH2 in three OC cell lines (Supplementary Figure S1D). EZH2 depletion not only suppressed cell proliferation but also attenuated the capacity of tumor sphere formation in OC cells (Supplementary Figure S1E and F). The oncogenic effect of EZH2 was further validated in vivo using OVCAR8 cells harboring the same system; downregulation of EZH2 expression following doxycycline treatment significantly inhibited xenograft tumor growth (Supplementary Figure S1G and H). These results provide strong evidence that EZH2 functions as a bona fide oncogene in OC.

To determine whether the catalytic activity of the SET domain is required for the oncogenic function of EZH2, we generated OVCAR8 and OVCAR5 cells stably expressing EZH2 or EZH2- $\Delta$ SET (lacking the SET domain) with the EZH2 inducible knockdown construct shEZH2#2. We introduced a silent point mutation at the EZH2#2 shRNA target site in the cloned EZH2 and EZH2- $\Delta$ SET gene sequences, which enabled us to study the differential effect of endogenous and ectopic gene expression. As expected, ectopic expression of EZH2 but not the EZH2- $\Delta$ SET restored the H3K27me3 level, which was reduced upon EZH2 silencing (Fig. 2H and Supplementary Figure S1I). However, both EZH2 and EZH2- $\Delta$ SET were able to rescue the suppressed tumor growth and tumor sphere formation induced by EZH2 silencing (Fig. 2I-K and Supplementary Figure S1J-H). Collectively, these results demonstrate that EZH2 promotes OC initiation and proliferation independently of its catalytic activity in OC.

#### **EZH2 noncanonically occupies promoters associated with metabolic genes**


To systematically investigate the gene-regulatory roles of EZH2 in OC, we carried out integrative analysis of ChIP-Seq data to profile the genome-wide occupancy of EZH2, H3K27me3 and SUZ12, a subunit in the PRC2 complex, in OVCAR8 cells. A large majority of EZH2 peaks lacked H3K27me3 and SUZ12 binding and were termed as EZH2-solo binding sites, and only a small subset of

EZH2 peaks overlapped with H3K27me3 and SUZ12 peaks, specifying canonical EZH2-ensemble binding sites (Fig. 3A-C). Approximately 50% of the EZH2-solo peaks were located at promoters (Fig. 3D). To confirm that these EZH2 solo binding sites are active promoters, an additional chromatin mark H3K4me3 was analyzed. Compared to the EZH2 ensemble and H3K27me3 solo binding sites, the EZH2 solo binding sites were overwhelmingly enriched in the H3K4me3 peaks (Fig. 3E and F). These results demonstrate that EZH2 solo binding sites are prevalent in OC and potentially regulate gene activation, differing from the canonical roles of the PRC2 complex.

To define the EZH2 solo target genes in OC, we performed RNA-Seq analysis in OVCAR8 cells upon DZNep treatment or silencing of EZH2. The transcriptional changes occurring in response to the two different approaches of EZH2 depletion were highly correlated (Fig. 3G). DZNep treatment resulted in upregulation of 833 genes and downregulation of 850 genes, while silencing of EZH2 caused upregulation of 1007 genes and downregulation of 1127 genes (Fig. 3G). Since the non-canonical function of EZH2 is to activate gene expression, genes downregulated upon EZH2 reduction were regarded as potential EZH2 potential targets. The 617 overlapping downregulated genes were further intersected with the EZH2 solo peak genes, and the resulting 251 overlapping genes enriched in EZH2 and H3K4me3 peaks but not H3K27me3 or SUZ12 peaks were defined as EZH2 solo targets (Fig. 3H). Gene set enrichment analysis (GSEA) using the KEGG and Reactome databases revealed that the most significantly negatively enriched pathways upon EZH2 depletion were metabolic signaling pathways (Fig. 3I), suggesting a role of EZH2 in metabolic regulation in OC. Furthermore, we identified 57 EZH2 solo targets contributing to the metabolic signaling pathways overlapping between the DZNep treatment and EZH2 silencing groups. The expression profiles of these 57 metabolic genes were further verified in normal ovarian and ovarian tumor tissues from the TCGA cohort and GTEx project. Twelve of these 57 genes were upregulated ( $\log_2\text{foldchange} > 1$ ,  $p\text{-value} < 0.05$ ) in ovarian cancer (Fig. 3J). Additionally, these 12 genes were downregulated upon both pharmacological and genetic EZH2 depletion, implying that EZH2 plays its oncogenic role partially via these genes (Fig. 3J). Taken together, these results indicate that the noncanonical roles of EZH2 in OC might be associated with metabolic rewiring.

#### **EZH2 transcriptionally upregulates IDH2 to promote metabolic rewiring**

OC was previously found to exhibit metabolic heterogeneity, and OXPHOS is one of the major mechanisms of energy production in OC cells [25]. Interestingly, the



**Fig. 3** EZH2 noncanonically occupies promoters associated with metabolic genes

(A-B) Averaged signal intensities (A) and heatmaps (B) for EZH2, H3K27me3 and SUZ12  $\pm 2$  kb from the centres of EZH2 or H3K27me3 peaks in OVCAR8 cells

(C) Venn diagram showing the significant overlap between EZH2 and H3K27me3 binding sites identified in OVCAR8 cells

(D) Pie-chart plot showing the genomic distribution of peaks with EZH2-solo binding in OVCAR8 cells

(E-F) Averaged signal intensities (E) and heatmaps (F) for EZH2, H3K27me3, SUZ12 and H3K4me3  $\pm 2$  kb from the centres of EZH2-solo, EZH2-ensemble or H3K27me3-solo peaks in OVCAR8 cells

(G) Scatterplot showing log2 fold change of genes expression in OVCAR8 cells after DZNep treatment or doxycycline-induced EZH2 silencing. Significant differential expression genes (DEGs) upon either treatments are indicated in blue color, upregulated DEGs in both groups are indicated in orange color, downregulated DEGs in both groups are indicated in green color. Spearman correlation between all genes is shown as a black line ( $R = 0.846$ ,  $p < 0.0001$ )

(H) Venn diagram showing the significant overlap between 617 EZH2 potential targets and EZH2-solo peaks associated genes in OVCAR8 cells. Averaged signal intensities for EZH2, H3K27me3, SUZ12 and H3K4me3  $\pm 2$  kb from the TSS of overlap genes are shown

(I) Gene set enrichment analysis for the 251 EZH2 solo targets using the KEGG and Reactome gene sets. Metabolism-related pathways are among the most enriched (left). The  $-\log_{10}(P\text{-value})$  of metabolism-related pathways are shown (right)

(J) Metabolism-related genes are upregulated in ovarian cancer tissues, and down regulated after EZH2 reduction. A heatmap showing the relative expression of top 10 metabolic genes in (H) by calculating their Z-score in indicated RNA-Seq data

genes encoding isocitrate dehydrogenase 2 (IDH2) and oxoglutarate dehydrogenase L (OGDHL), which participate in oxidative phosphorylation (OXPHOS) and the tricarboxylic acid cycle (TCA cycle), were among the top 10 genes upregulated when EZH2 was inhibited (Fig. 3J and Fig. 4A). In addition, we performed gene expression profiling analysis with the RNA-Seq data from the TCGA ovarian cancer cohort. KEGG pathway analysis showed that the oxidative phosphorylation pathway was significantly enriched in ovarian cancer tissues compared to normal ovarian tissues, suggesting that the TCA cycle or oxidative phosphorylation activity plays an important role in ovarian cancer development (**Supplementary Figure S2A**). These results raised the possibility that EZH2 is involved in the mitochondrial TCA cycle to promote OXPHOS in OC.

To determine whether EZH2 promotes TCA cycle activity, we next examined the mRNA levels of *IDH2* and *OGDHL* upon DZNep or GSK126 treatment in OVCAR8 and OVCAR4 cells. Interestingly, *IDH2* and *OGDHL* were downregulated upon treatment with DZNep but not GSK126, suggesting that EZH2 regulates the TCA cycle independently of its methyltransferase activity (Fig. 4B). We showed that IDH2, the rate-limiting enzyme for the TCA cycle, is significantly upregulated in OC, which prompted us to investigate the correlation between EZH2 and IDH2. We observed that the IDH2 level was concomitantly reduced upon doxycycline-induced EZH2 silencing (Fig. 4C), and that ectopic expression of *EZH2* or *EZH2-ΔSET* restored the level of IDH2 (Fig. 4D), indicating that *IDH2* might be transcriptionally regulated by EZH2. In addition, we further inserted the promoter and 5'UTR of *IDH2* (-1000~81 bp) into the pGL3-basic plasmid and performed a dual luciferase reporter assay after DZNep and GSK126 treatment in OVCAR8 and OVCAR4 cells. The transcriptional activity of the *IDH2* promoter was attenuated upon treatment with DZNep but not GSK126 (Fig. 4E). Furthermore, we performed a dual luciferase reporter assay in OVCAR8-sh*EZH2*#2 cells transduced with the *EZH2*- or *EZH2-ΔSET*-expressing plasmids. Doxycycline-induced EZH2 silencing decreased luciferase activity driven by the *IDH2* promoter, whereas ectopic expression of *EZH2* and *EZH2-ΔSET* restored *IDH2* promoter activity (Fig. 4F). Moreover, we examined the binding regions of EZH2, SUZ12 and H3K27me3 in the *IDH2* promoter by chromatin immunoprecipitation (ChIP). Compared with the IgG isotype control, the specific anti-EZH2 antibody but not the specific anti-SUZ12 or anti-H3K27me3 antibody bound directly to the region containing -600~400 bp in the *IDH2* promoter (Fig. 4G). In addition, in our ChIP-Seq data and the GSE180448 data, the binding peaks of EZH2 but not those of H3K27me3 or SUZ12 were located in the promoter region of *IDH2*, providing

further evidence supporting our hypothesis that EZH2 transcriptionally upregulates *IDH2* via a noncatalytic function (Fig. 4H) [17, 26]. These results demonstrated that EZH2 serves as a direct transcriptional regulator to promote *IDH2* expression in OC.


To confirm the regulatory effect of EZH2 on OXPHOS activity, we further examined the oxygen consumption rate (OCR) in OVCAR8 cells upon DZNep and GSK126 treatment. The basal and maximal OCRs were decreased upon treatment with DZNep but not GSK126 in OVCAR8 and OVCAR4 cells (Fig. 4I). Consistent with these findings, doxycycline induced *EZH2* silencing also resulted in significant reductions in the basal and maximal OCRs in OVCAR8 cells (Fig. 4J). Furthermore, we demonstrated that the OCR of cells was restored after genetic knockdown of EZH2 and restoration with wild-type or mutant EZH2 (**Supplementary Figure S2B**). These data support a role for EZH2 in the regulation of OXPHOS in OC cells.

#### Reduction of EZH2 impairs IDH2 dependent metabolic rewiring to suppress OC growth

To investigate whether the downregulation of *IDH2* mediated by EZH2 is clinically associated with OC, we performed IHC staining in our OC cohort and confirmed that IDH2 expression was positively correlated with EZH2 expression and that high expression of IDH2 predicted poor prognosis in OC patients (Fig. 5A-C). We further examined the colony formation and cell proliferation abilities upon silencing *IDH2* or *EZH2*. Consistent with the above findings, silencing of either *IDH2* or *EZH2* was sufficient to suppress OC cell growth (Fig. 5D and E). We next examined the product synthesized via IDH2, α-ketoglutarate (α-KG), in OVCAR8 cells treated with DZNep or GSK126. The data indicated that the level of α-KG was significantly decreased upon treatment with DZNep but not GSK126 (Fig. 5F). We further evaluated the cellular α-KG level in cells after genetic knockdown of EZH2 and replacement with wild-type or mutant EZH2, demonstrating that the α-KG level was partially restored in OVCAR8 cells with Dox-induced EZH2 silencing by ectopic expression of *EZH2* or *EZH2-ΔSET* (Fig. 5G). Moreover, when we supplemented cultures of OVCAR8 and OVCAR5 cells with α-KG after Dox-induced EZH2 silencing, the phenotype induced by EZH2 knockdown was partially rescued (Fig. 5H), suggesting that the oncogenic function of EZH2 in OC could be partially mediated by α-KG.

To examine whether the anticancer effect of EZH2 reduction is IDH2 dependent, we generated OVCAR8 cells stably expressing *IDH2* and containing the EZH2 inducible knockdown construct sh*EZH2*#2. *IDH2* overexpression counterbalanced the downregulation of *IDH2* mediated by doxycycline-induced *EZH2* silencing





**Fig. 4** EZH2 transcriptionally upregulates IDH2 to promote metabolic rewiring

(A) Diagram of TCA cycle. TCA cycle related genes in Fig. 3I are indicated in orange color

(B) qRT-PCR analysis of TCA cycle related genes in OVCAR8 and OVCAR4 cells upon 5μM DZNep or GSK126 treatment for 72 h. Data are presented as mean ± SD. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$


(C-D) qRT-PCR analysis of EZH2 and IDH2 levels upon Dox-induced EZH2 silencing in indicated cells. IDH2 level was concomitantly reduced upon Dox-induced EZH2 silencing (C), and ectopic expression of EZH2 or EZH2-ΔSET restored the level of IDH2 (D). Data are presented as mean ± SD. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$

(E-F) Dual-luciferase reporter assay of IDH2 promoter activity in OC cell lines upon pharmacological or genetic inhibition of EZH2. The OVCAR8 and OVCAR4 cells were treated with 5μM DZNep or GSK126 for 48 h before luciferase reporter assay (E). The indicated cells were treated with 1 μg/mL Dox for 48 h before luciferase reporter assay (F). Data are presented as mean ± SD. \*\* $P < 0.01$ , \*\*\* $P < 0.001$

(G) ChIP assay in OVCAR8 cells. A specific antibody against EZH2 but not isotype IgG, SUZ12, or H3K27me3 could capture the fragment containing EZH2 binding site in the IDH2 promoter region, which was amplified by specific primers (top) by qRT-PCR (bottom)

(H) ChIP-seq profiling showed the ChIP-seq signal for EZH2, H3K4me3, H3K27me3 and SUZ12 at the genomic loci of IDH2 in OVCAR8 cells. ChIP-seq profiling also showed the ChIP-seq signal for EZH2 and H3K27me3 in two MLL1-rearranged leukaemia cell lines in GSE180448.

(I-J) OCR assays upon pharmacological (I) or genetic (J) inhibition of EZH2. Representative OCR pattern as a function of time (in min), normalized to total protein levels. Cells were pretreated with 5 μM DZNep, GSK126 or 1 μg/mL doxycycline for 72 h before OCR measurement. Data are shown as mean ± SD of three replicates per treatment



**Fig. 5** Reduction of EZH2 impairs IDH2 dependent metabolic rewiring to suppress OC growth

(A) Representative images of EZH2 and IDH2 staining in OC tissues (n = 105). Scale bar: 100  $\mu$ m

(B) IDH2 level was strongly positively correlated with EZH2 level in the OC cohort (n = 105). *P* value was determined by Pearson's correlation test

(C) Kaplan-Meier survival analysis for the OC cohort (n = 105), which was divided into IDH2<sup>high</sup> and IDH2<sup>low</sup> subgroups based on the cutoff (cutoff = 5) calculated by the X-Tile software. The *P* value was calculated by log-rank test. \*\**P* < 0.01

(D) Colony formation assay in OVCAR8 and OVCAR4 cells transfected with IDH2 or EZH2 siRNA. Cells were cultured for 12 days. Growth medium was changed every 3 days. Images are representative of three independent experiments

(E) Cell growth curve of OVCAR8 and OVCAR4 cells transfected with IDH2 or EZH2 siRNA for 96 h. Data are presented as mean  $\pm$  SD. \**P* < 0.05, \*\**P* < 0.01

(F-G)  $\alpha$ -KG assay in OVCAR8 cells upon DNZep, GSK126 treatment (F) or in OVCAR8-shEZH2#2 cells ectopic expressing wildtype or mutant EZH2 (G). The OVCAR8 cells were treated with 2  $\mu$ M DNZep, 5  $\mu$ M GSK126 or 1  $\mu$ g/mL doxycycline for 72 h before  $\alpha$ -KG assay. Data are presented as the mean  $\pm$  SD. \*\**P* < 0.01, \*\*\**P* < 0.001

(H) Colony formation assay in OVCAR8 and OVCAR5 cells upon Dox-induced EZH2 silencing with or without  $\alpha$ -KG supplementation. Cells were treated with 5 ng/mL doxycycline for 12 days. Medium with or without 1 mM  $\alpha$ -KG was changed and doxycycline was also replenished every 2 days. Images are representative of three independent experiments

(I) Colony formation assay in OVCAR8-shEZH2#2 cells with ectopic IDH2 expression. Cells were treated with 5 ng/mL doxycycline for 12 days. Growth medium was changed and doxycycline was also replenished every 3 days. Images are representative of three independent experiments. Immunoblot analysis of EZH2 and IDH2 levels in indicated samples. Cells were treated with or without Dox for 72 h before being harvested. GAPDH was used as loading controls

(J) Cell growth curve of OVCAR8-shEZH2#2 cells with ectopic IDH2 expression upon 1  $\mu$ g/mL doxycycline treatment for 96 h. Data are presented as the mean  $\pm$  SD. \**P* < 0.05

(K) Representative OCR pattern as a function of time (in min), normalized to total protein levels. Cells were incubated in the absence or presence of 1  $\mu$ g/mL doxycycline for 72 h before OCR measurement. Data are shown as mean  $\pm$  SD of three replicates per treatment

(Fig. 5I). Next, we studied the tumorigenic behaviors of *IDH2*-overexpressing cells upon doxycycline induced *EZH2* silencing. Ectopic expression of *IDH2* partially rescued the reductions in colony formation and cell proliferation occurring upon doxycycline-induced *EZH2* silencing (Fig. 5I and J). Furthermore, we found that the basal and maximum OCRs were restored in *IDH2*-overexpressing cells even upon doxycycline induced *EZH2* silencing (Fig. 5K). Taken together, these results indicated that a reduction in *EZH2* expression impairs *IDH2* dependent metabolic rewiring to suppress OC growth.

#### Targeting *EZH2*-mediated metabolic rewiring exhibits potential therapeutic efficacy in preclinical models of OC


To further validate the role of *EZH2*-mediated metabolic rewiring in OC patients, we validated our findings in two primary OC cell lines derived from OC patients. Similarly, only the DZNep and YM281 inhibited the proliferation of patient-derived OC cells. Neither GSK126 nor EPZ-6438 exhibited growth inhibitory effects on in these patient-derived OC cell lines (Fig. 6A and B, **Supplementary Figure S3A**). We found that both DZNep and YM281 could reduce the levels of *EZH2* and H3K27me<sub>3</sub>, whereas GSK126 and EPZ-6438 could only decrease only the level of H3K27me<sub>3</sub> and did not affect the *EZH2* protein levels in patient-derived OC cells (Fig. 6C).

Since chemoresistance has become a major obstacle in the treatment of OC, we established a patient-derived xenograft (PDX) model from a patient with chemoresistant (carboplatin- and Taxol-resistant) OC to study the efficacy of DZNep and EPZ6438 (**Supplementary Figure S3B and C**). The in vivo study indicated that DZNep but not EPZ-6438 significantly suppressed tumor growth (Fig. 6D and E). Treatment with either of these inhibitors resulted in a minimal body weight loss, suggesting that both inhibitors had low toxicity (Fig. 6F). In DZNep treated tumors, the Ki67 level was concomitantly decreased with that of *EZH2* but not with that of H3K27me<sub>3</sub>, further indicating that the oncogenic role of *EZH2* is independent of its catalytic activity (Fig. 6G and **Supplementary Figure S3D**). To further confirm that *EZH2* inhibition can suppress the metabolic rewiring, we next examined the  $\alpha$ -KG level in PDX tumors upon treatment with *EZH2* inhibitors. The data showed that the  $\alpha$ -KG level was significantly decreased upon DZNep treatment but not EPZ6438 treatment (Fig. 6H). The  $\alpha$ -KG level is consistent with the levels of *EZH2* and *IDH2* (Fig. 6G and **Supplementary Figure S3D**), suggesting that  $\alpha$ -KG is a key metabolite in OC that could predict poor prognosis. Collectively, these results demonstrated that inhibitors resulting in a reduction in *EZH2* expression but not inhibition of its catalytic activity exhibit a potential therapeutic efficacy in patients with chemoresistant OC.

## Discussion

*EZH2* is gaining attention as an attractive therapeutic target for ovarian cancer [27, 28]. *EZH2* is thought to drive tumorigenesis and progression in ovarian cancer through repression of tumor suppressor genes by promoting trimethylation of histone H3K27 (H3K27me<sub>3</sub>) in the promoter regions, with the expression level of *EZH2* being positively correlated with the H3K27me<sub>3</sub> level, as Sun et al. reported [11]. Other reports have described a high level of H3K27me<sub>3</sub> as an indicator of good prognosis; however, H3K27me<sub>3</sub> is usually lost in ovarian cancer, contradictory to the oncogenic role of *EZH2* as the H3K27me<sub>3</sub> methyltransferase [12]. In this study, we showed that a subset of patients with OC with high expression of *EZH2* but a low H3K27me<sub>3</sub> level exhibited the worst prognosis, which is consistent with previous studies [12, 28]. Since the level of H3K27me<sub>3</sub> is hypothesized to be determined by the balance between the activities of the PRC2 complex and the demethylases JMJD3 and UTX, the roles by which JMJD3 and UTX contribute to the level of H3K27me<sub>3</sub> in some OC patients warrant further investigation. In other cancers, *EZH2* has been reported to activate oncogenic pathways in a PRC2-independent manner [15–17]. In our study, we demonstrated that in OC, *EZH2* transcriptionally upregulated *IDH2* to potentiate metabolic rewiring by enhancing tricarboxylic acid cycle (TCA cycle) activity, which provide a novel mechanism by *EZH2* to promote tumor growth. Our study improved the understanding of the relationship between *EZH2* and H3K27me<sub>3</sub> in OC, and began to delve into the mechanisms of the noncanonical roles of *EZH2* as a transcriptional activator and its impact on the selection of therapeutic strategies (Fig. 7).

Currently, *EZH2* inhibitors are being tested in a number of clinical trials and have been shown to benefit patients with certain hematological malignancies harboring activating mutations in *EZH2* [28, 29]. *EZH2* inhibitors can be classified into three types based on their mechanisms: inhibitors of *EZH2* methyltransferase activity, inhibitors that dissociate the PRC2 complex, and inhibitors triggering *EZH2* degradation [20]. The anticancer efficacy of the different classes of *EZH2* inhibitors is dependent on the roles of *EZH2* in the tumor. In our study, DZNep and YM281, two inhibitors triggering *EZH2* degradation, exhibited potent anticancer efficacy in OC cell lines and xenografts, but GSK126 and EPZ-6438, which inhibit the methyltransferase activity of *EZH2*, did not. Therefore, our findings revealed a noncanonical role of *EZH2* in reprogramming metabolism in OC. We further demonstrated in in vivo models that inhibitors triggering *EZH2* degradation have promising application in OC treatment, suggesting that the design of more specific, more efficient and safer *EZH2* degraders is an important direction in the development of drugs for OC.



**Fig. 6** Targeting EZH2 mediated metabolic rewiring exhibits potential therapeutic efficacy in preclinical models of OC

(A) Colony formation assay in two primary OC cell lines derived from two OC patients (POVC17, POVC15). Cells were treated with DMSO, DZNep (1  $\mu$ M), YM281 (5  $\mu$ M), GSK126 (5  $\mu$ M) or EPZ-6438 (5  $\mu$ M) for 12 days. Growth medium was changed and inhibitors were also replenished every 3 days. Images are representative of three independent experiments unless stated otherwise

(B) Cell growth curve of two OC patient-derived primary tumor cell lines treated with DMSO, DZNep (1  $\mu$ M), YM281 (5  $\mu$ M) or GSK126 (5  $\mu$ M) for 96 h. Data are presented as the mean  $\pm$  SD. \*\*\* $P$  < 0.001

(C) Immunoblotting analysis of EZH2 and H3K27me3 levels in two OC patient-derived primary tumor cell lines upon EZH2 inhibitors treatment. Cells were treated with DMSO, DZNep (1  $\mu$ M), YM281 (5  $\mu$ M), GSK126 (5  $\mu$ M) or EPZ-6438 (5  $\mu$ M) for 72 h

(D) Tumor growth of PDX models in NOD-SCID mice treated with saline as control, EPZ-6438 at 200 mg/kg intragastrically daily, or DZNep at 1 mg/kg intraperitoneally twice a week (n = 6 per group). Data are presented as mean  $\pm$  SD. \*\*\* $P$  < 0.001 (Two-way ANOVA with Tukey's post hoc test)


(E) Bar graph showing the tumor weight on the 26th day post-treatment week (n = 6 per group). Data are presented as mean  $\pm$  SD. \*\* $P$  < 0.01

(F) Body weight of each mouse post-treatment. Data are presented as mean  $\pm$  SD.

(G) IHC analysis of EZH2, H3K27me3, IDH2 and Ki67 levels in the excised tumors from PDX models. Data are presented as mean  $\pm$  SD. \*\* $P$  < 0.01, \*\*\* $P$  < 0.001

(H)  $\alpha$ -KG assay in PDX tumors upon EPZ6438 or DZNep treatment. Data are presented as mean  $\pm$  SD. \*\*\* $P$  < 0.001





**Fig. 7** Schematic model illustrating the mechanism of EZH2 potentiating metabolic rewiring in OC

Overexpressed EZH2 transcriptionally regulates TCA related genes such as *IDH2*, to enhance the TCA cycle, which promotes metabolic rewiring in OC cells. Small molecules trigger EZH2 degradation, rather than catalytic inhibition, to suppress the transcription of TCA-related genes and significantly block OC growth in vitro and in vivo

The great need for energy to support tumor cell expansion is satisfied by metabolic reprogramming, which is defined as a key hallmark of cancer [30]. Accumulating evidence has revealed that aerobic glycolysis (the typical Warburg effect) is not the sole mechanism that tumor cells preferentially employ to produce energy [31–33]. OXPHOS is also used to produce the amount of energy required for proliferation in some tumor types, such as OC [25]. In our study, we revealed a noncanonical mechanism that implicates EZH2 in the regulation of glucose metabolism. We demonstrated that EZH2 directly promotes *IDH2* transcription to enhance glucose metabolism via OXPHOS in OC cells. *IDH2* is an important enzyme in the TCA cycle that catalyzes the production of  $\alpha$ -KG. Certain active site mutations in *IDH2* enable the production of 2-hydroxyglutarate (2-HG) in place of  $\alpha$ -KG, and are frequently found in multiple types of tumors [34]. 2-HG, a cancer cell-autonomous oncometabolite, promotes tumor initiation by modifying DNA and histone methylation [35]. However, such mutations in *IDH2* seldom occur in ovarian cancer, implying that overexpression of *IDH2* promotes OC progression by facilitating

TCA cycle activity to produce enough energy and not by producing 2-HG [36]. Moreover, *EZH2* and *IDH2* are overexpressed in ovarian cancer stem cells, which favor OXPHOS over glycolysis for energy production [10, 37]. Interestingly, the TCA cycle intermediate  $\alpha$ -KG, the product of *IDH2*, enables the maintenance of H3K27 hypomethylation [38, 39]. Our study demonstrated that EZH2 transcriptionally upregulates *IDH2*, which increases the cellular level of  $\alpha$ -KG. Therefore, the worse prognosis of patients with the  $EZH2^{\text{high}}/H3K27\text{me}3^{\text{low}}$  subtype of OC may be due to the collective actions of two pathways: EZH2-driven metabolic rewiring and  $\alpha$ -KG-mediated suppression of H3K27me3.

Herein, we observed that EZH2 regulates OXPHOS by promoting *IDH2* expression through a methyltransferase independent mechanism, a finding that highlights the importance of noncanonical EZH2 signaling in ovarian carcinogenesis. However, there are several limitations to this study; for example, the noncanonical role of EZH2 discovered herein is found in only approximately one-quarter of OC patients. Furthermore, the mechanism of H3K27 trimethylation in the  $H3K27\text{me}3^{\text{high}}/EZH2^{\text{low}}$

subgroup remains to be elucidated. Despite these limitations, our study suggests that therapeutic targeting of the EZH2-IDH2 axis might be a promising strategy for combating ovarian cancer. We found several EZH2 inhibitors effective for this purpose, but further clinical validation is needed before their application in OC treatment.

## Conclusion

We demonstrated that EZH2 transcriptionally upregulated IDH2 to potentiate metabolic rewiring by enhancing TCA cycle activity, which contributed to the growth of OC. Our study revealed a noncanonical role of EZH2 in OC and demonstrated that targeting the catalysis-independent activity of EZH2 is a potential therapeutic strategy.

## Abbreviations

$\alpha$ -KG	$\alpha$ -ketoglutarate
AR	Androgen receptor
ChIP-Seq	Chromatin immunoprecipitation sequencing
EZH2	Enhancer of zeste homolog 2
EZH2- $\Delta$ SET	EZH2 with SET domain deletion
GSEA	Gene set enrichment analysis
GTEX	Genotype-Tissue Expression
IDH2	Isocitrate dehydrogenase 2
IHC	Immunohistochemistry
NKTL	Natural killer/T-cell lymphoma
OC	Ovarian cancer
OCR	Oxygen consumption rate
OD	Optical density
OXPPOS	Oxidative phosphorylation
PDX	Patient derived xenograft
PRC2	Polycomb repressive complex 2
qRT-PCR	Quantitative real-time PCR
RNA-Seq	RNA sequencing
SAM	S-adenosylmethionine
TCA	Tricarboxylic acid
TCGA	The Tumor Genome Atlas

## Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12943-023-01786-y>.

Supplementary Material 1

## Acknowledgements

We thank all the patients who donated samples for this study. We appreciate Dicong Zhu for the kind assistance of the project. We thank the platform of metabolomics (Center for Precision Medicine, Sun Yat-sen University) for the help of technical support.

## Authors' contribution

Jianfeng Chen, and Jing Tan conceived, designed, and supervised the study; Jianfeng Chen, Yulin Wang and Xian Zeng performed the experiments; Peng Deng, Shini Liu, and Peiyong Guan analyzed and interpreted the data (e.g., statistical analysis, biostatistics, computational analysis); Ying Xiong provided patient samples; Zhaoliang Yu provided pathology expertise; Peng Deng, Zhaoliang Yu, Rong Xiao, Yichen Sun, Jiaxin Yin, Lizhen Liu, Yali Wang, Peili Wang, and Jing Han Hong provided material and technical support; Shijun Wen provided the EZH2 inhibitor YM281 for this study, Jianfeng Chen and Jing Tan wrote and revised the manuscript; Choonkiat Ong, Jason Yongsheng Chan and Qiang Yu provided a kind suggestion for the manuscript writing. All the authors have given their consent to publish this study.

## Funding

This work was supported by the National Natural Science Foundation of P. R. China (81972596, 81772963 and 81773279), Guangdong Innovative and Entrepreneurial Research Team Program (2016ZT06S638, 2016ZT06S252), Guangzhou Science and Technology Program (2023B01J1004), the Natural Science Foundation of Guangdong Province (2021A1515011131).

## Data Availability

The datasets generated and/or analysed during the current study are available in the Research Data Deposit public platform ([www.researchdata.org.cn](http://www.researchdata.org.cn)) with approval number RDDB2023743679.

## Declarations

### Ethics approval and consent to participate

Informed consent was obtained from the patients who provided the tissue, and all procedures were approved by the medical ethics committee of the Sun Yat-sen University Cancer Center (Guangzhou, China). All animal studies were conducted in compliance with animal protocols approved by the Institutional Animal Care and Use Committee of Sun Yat-sen University Cancer Center (Guangzhou, China).

### Competing interests

The authors declare no potential conflicts of interest.

### Author details

<sup>1</sup>State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China

<sup>2</sup>State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, 651 East Dongfeng Road, Guangzhou, Guangdong 510060, P. R. China

<sup>3</sup>Cancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore, Singapore

<sup>4</sup>Department of Oncology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangdong 510060, P. R. China

<sup>5</sup>Department of Laboratory Medicine, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangdong 510060, P. R. China

<sup>6</sup>Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510655, P. R. China

<sup>7</sup>Laboratory of Cancer Epigenome, Division of Medical Sciences, National Cancer Centre Singapore, Singapore, Singapore

<sup>8</sup>Genome Institute of Singapore, A\*STAR, Singapore, Singapore

<sup>9</sup>Center of Medical Research, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangdong 510060, P. R. China

<sup>10</sup>Lymphoma Genomic Translational Research Laboratory, Cellular and Molecular Research, National Cancer Centre Singapore, Singapore, Singapore

Received: 2 November 2022 / Accepted: 9 May 2023

Published online: 20 May 2023

## References

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. *CA Cancer J Clin.* 2021;71:7–33.
2. Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A, Siegel RL. Ovarian cancer statistics, 2018. *CA Cancer J Clin.* 2018;68:284–96.
3. Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. *The Lancet.* 2019;393:1240–53.
4. Cortez AJ, Tudrej P, Kujawa KA, Lisowska KM. Advances in ovarian cancer therapy. *Cancer Chemother Pharmacol.* 2018;81:17–38.
5. Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C. Emerging landscape of oncogenic signatures across human cancers. *Nat Genet.* 2013;45:1127–33.

6. Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. *Nature*. 2011;474:609–15.
7. Li H, Cai Q, Godwin AK, Zhang R. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells. *Mol Cancer Res*. 2010;8:1610–8.
8. Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, Armaiz-Pena GN, Hu W, Stone RL, Munkarah A, et al. Regulation of tumor angiogenesis by EZH2. *Cancer Cell*. 2010;18:185–97.
9. Yang Q, Yang Y, Zhou N, Tang K, Lau WB, Lau B, Wang W, Xu L, Yang Z, Huang S, et al. Epigenetics in ovarian cancer: premise, properties, and perspectives. *Mol Cancer*. 2018;17:109.
10. Rizzo S, Hersey JM, Mellor P, Dai W, Santos-Silva A, Liber D, Luk L, Tittley I, Carden CP, Box G, et al. Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. *Mol Cancer Ther*. 2011;10:325–35.
11. Sun S, Yang Q, Cai E, Huang B, Ying F, Wen Y, Cai J, Yang P. EZH2/H3K27Me3 and phosphorylated EZH2 predict chemotherapy response and prognosis in ovarian cancer. *PeerJ*. 2020;8:e9052.
12. He WP, Li Q, Zhou J, Kung HZS, Guan HF, Xie XY, Yang D. Decreased expression of H3K27me3 in human ovarian carcinomas correlates with more aggressive tumor behavior and poor patient survival. *Neoplasia*. 2015;62:932–7.
13. Lee ST, Li Z, Wu Z, Au M, Guan P, Karuturi RK, Liou YC, Yu Q. Context-specific regulation of NF-kappaB target gene expression by EZH2 in breast cancers. *Mol Cell*. 2011;43:798–810.
14. Mahara S, Lee PL, Feng M, Tergaonkar V, Chng WJ, Yu Q. HIF1-alpha activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer. *Proc Natl Acad Sci U S A*. 2016;113:E3735–3744.
15. Yan J, Ng SB, Tay JL, Lin B, Koh TL, Tan J, Selvarajan V, Liu SC, Bi C, Wang S, et al. EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity. *Blood*. 2013;121:4512–20.
16. Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis RT, Wu X, Stack EC, Loda M, Liu T, et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is polycomb-independent. *Science*. 2012;338:1465–9.
17. Kim J, Lee Y, Lu X, Song B, Fong KW, Cao Q, Licht JD, Zhao JC, Yu J. Polycomb and methylation-independent roles of EZH2 as a transcription activator. *Cell Rep*. 2018;25:2808–2820.e2804.
18. Kim KH, Roberts CW. Targeting EZH2 in cancer. *Nat Med*. 2016;22:128–34.
19. Chase A, Cross NC. Aberrations of EZH2 in cancer. *Clin Cancer Res*. 2011;17:2613–8.
20. Duan R, Du W, Guo W. EZH2: a novel target for cancer treatment. *J Hematol Oncol*. 2020;13:104.
21. Chapman-Rothe N, Curry E, Zeller C, Liber D, Stronach E, Gabra H, Ghaem-Maghami S, Brown R. Chromatin H3K27me3/H3K4me3 histone marks define gene sets in high-grade serous ovarian cancer that distinguish malignant, tumour-sustaining and chemo-resistant ovarian tumour cells. *Oncogene*. 2013;32:4586–92.
22. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. *Nucleic Acids Res*. 2017;45:W98–W102.
23. Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, Karuturi RK, Tan PB, Liu ET, Yu Q. Pharmacologic disruption of polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. *Genes Dev*. 2007;21:1050–63.
24. Tu Y, Sun Y, Qiao S, Luo Y, Liu P, Jiang ZX, Hu Y, Wang Z, Huang P, Wen S. Design, synthesis, and evaluation of VHL-Based EZH2 degraders to enhance therapeutic activity against Lymphoma. *J Med Chem*. 2021.
25. Gentric G, Kieffer Y, Mieulet V, Goundiam O, Bonneau C, Nemat F, Hurbain I, Raposo G, Popova T, Stern MH, et al. PML-Regulated mitochondrial metabolism enhances Chemoresensitivity in Human ovarian cancers. *Cell Metab*. 2019;29:156–173.e110.
26. Wang J, Yu X, Gong W, Liu X, Park KS, Ma A, Tsai YH, Shen Y, Onikubo T, Pi WC, et al. EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis. *Nat Cell Biol*. 2022;24:384–99.
27. Li H, Zhang R. Role of EZH2 in epithelial ovarian Cancer: from Biological Insights to Therapeutic Target. *Front Oncol*. 2013;3:47.
28. Jones BA, Varambally S, Arend RC. Histone methyltransferase EZH2: a therapeutic target for ovarian Cancer. *Mol Cancer Ther*. 2018;17:591–602.
29. Kurmasheva RT, Sammons M, Favours E, Wu J, Kurmashev D, Cosmopoulos K, Keilhack H, Klaus CR, Houghton PJ, Smith MA. Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program. *Pediatr Blood Cancer*. 2017, 64.
30. Vander Heiden MG, DeBerardinis RJ. Understanding the Intersections between Metabolism and Cancer Biology. *Cell*. 2017;168:657–69.
31. Vazquez F, Lim JH, Chim H, Bhalla K, Girmun G, Pierce K, Clish CB, Granter SR, Widlund HR, Spiegelman BM, Puigserver P. PGC1alpha expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. *Cancer Cell*. 2013;23:287–301.
32. Caro P, Kishan AU, Norberg E, Stanley IA, Chapuy B, Ficarro SB, Polak K, Tondera D, Gounarides J, Yin H, et al. Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma. *Cancer Cell*. 2012;22:547–60.
33. Farge T, Saland E, de Toni F, Aroua N, Hosseini M, Perry R, Bosc C, Sugita M, Stuan L, Fraisse M, et al. Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism. *Cancer Discov*. 2017;7:716–35.
34. Yang H, Ye D, Guan KL, Xiong Y. IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives. *Clin Cancer Res*. 2012;18:5562–71.
35. Du X, Hu H. The roles of 2-Hydroxyglutarate. *Front Cell Dev Biol*. 2021;9:651317.
36. Dahl ES, Buj R, Leon KE, Newell JM, Imamura Y, Bitler BG, Snyder NW, Aird KM. Targeting IDH1 as a prosenescent therapy in high-grade Serous Ovarian Cancer. *Mol Cancer Res*. 2019;17:1710–20.
37. Pasto A, Bellio C, Pilotto G, Ciminale V, Silic-Benussi M, Guzzo G, Rasola A, Frasson C, Nardo G, Zulato E, et al. Cancer stem cells from epithelial ovarian cancer patients privilege oxidative phosphorylation, and resist glucose deprivation. *Oncotarget*. 2014;5:4305–19.
38. Chung C, Sweha SR, Pratt D, Tamrazi B, Panwalkar P, Banda A, Bayliss J, Hawes D, Yang F, Lee HJ, et al. Integrated metabolic and epigenomic reprogramming by H3K27M mutations in diffuse intrinsic pontine gliomas. *Cancer Cell*. 2020;38:334–349.e339.
39. Zhao K, Miao H. Targeting metabolic/epigenetic pathways: a potential strategy for cancer therapy in diffuse intrinsic pontine gliomas. *Signal Transduct Target Ther*. 2020;5:226.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.